Samsrita Labs Ltd (SAMM)

Samsrita Labs Limited operates as a bio-pharmaceutical company in India. The company offers DNA, RNA, and chromosomal based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and pre-natal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype and fluorescence in-situ hybridization analysis. It is also involved in stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, as well as focuses on the body organs of liver, pancreas, neural, cardiac, vascular, renal, and ortho. In addition, the company engages in new drug discovery, including therapeutic areas for wilson’s disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular disease, cystinosis, and huntington’s disease. Further, it provides molecular prognosis and diagnostics services in the areas of cytogenetics, pharmacogenomics, pathology, radiology, hematology, biochemistry, microbiology, and others; and develops liver support device, bioengineering implantable humanized nerve conduits, implantable nanochips carrying insulin producing cells, and extra-corporeal device. The company also offers academic services; and hospital services. It provides molecular diagnostics services to patients, private consultants, hospitals, and other healthcare institutions. The company was formerly known as Dr Habeebullah Life Sciences Limited and changed its name to Samsrita Labs Limited in October 2022. Samsrita Labs Limited was incorporated in 1996 and is based in Hyderabad, India.